Clinical OMICs - Issue 3 - (Page 20)

Clinical OMICs INNOVATOR Promoting Wellness & Demystifying Disease: The 100K Project Leroy Hood, M.D., Ph.D., and Nathan D. Price, Ph.D. W e believe that a longitudinal, Framingham-like study of 100,000 well individuals (hereafter termed the 100K project) and their dynamical data clouds could transform medicine by 1) providing scientifically validated metrics for wellness, 2) allowing one to study the earliest origins of disease in an individual and 3) allow one to follow the entire progression of a disease from its beginning to end. This proposal would allow us to study the initiation and progression of all common diseases and, from that, learning how to predict and prevent these diseases would revolutionize healthcare. Complexity, Disease, and Systems Medicine Contemporary medicine is challenged by the incredible complexity of physiology and disease. Each individual has unique genetic and environmental contexts. Clearly the traditional 20 Clinical OMICs May 15, 2014 reductionist approaches to disease are insufficient to effectively deconvolute this complexity. Over the last 10 years systems approaches have increasingly been employed, leading to a new discipline designated systems medicine, which has two striking features. First, each patient will be surrounded by a virtual cloud of billions of data points, and we will have the analytical tools to reduce this enormous dimensionality to simple hypotheses of how to optimize wellness and minimize disease for each individual. Second, the data can be integrated and modeled to determine the health and disease-associated states of the "network of networks" operating in each individual. These interconnected networks manage diverse types of biological information that operate at the chromosomal, molecular, cellular, organ and even individual levels. In disease, these networks become perturbed and this alters the information they manage and the func- tions they carry out. Delineating this altered and disease-perturbed information provides insights into disease mechanisms, diagnostic markers, and drug target candidates. Systems medicine has reached a tipping point and its emerging technologies and systems-driven strategies are already beginning to alter the practice of medical discovery and of healthcare. Many strategies are helping to drive this future, such as using the complete genome sequencing of families to more rapidly identify disease genes, studying disease dynamics in model organisms to provide fundamental insights into disease mechanisms, pioneering systems approaches to blood diagnostics to create powerful biomarker panels that can inform medical decisions, stratifying diseases and patients into distinct subgroups for more personalized treatments, and using computational analyses of disease-perturbed networks to identify new classes of drug target candidates. www.clinicalomics.com http://www.clinicalomics.com

Table of Contents for the Digital Edition of Clinical OMICs - Issue 3

Contents

Clinical OMICs - Issue 3

https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol3iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_vol2iss1
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue15
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue14
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue13
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue12
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue11
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue10
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue9
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue8
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue7
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue6
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue5
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue4
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue3
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue2
https://www.nxtbook.com/nxtbooks/gen/clinical_omics_issue1
https://www.nxtbookmedia.com